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SHORT COMMUNICATION
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in
advanced colorectal cancer: poor response rate in unselected patients
CL Hanna, FE McKinna, LB Williams, D Morrey, M Adams, MD Mason and TS Maughan
Velindre Hospital. Cardiff CF4 7XL, UK.
Snuunary We have conducted a retrospective study of high-dose folimc acid and 5-fluorouracil in % patients
with advanced colorectal cancer. Patients received 200mg m - (maximum 300-350 mg) folinic acid by
infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400mg m - then an infusion of 5-fluorouracil
600 mg m -' over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for four
cycles; thereafter patients with objective response continued to a maximum of eight cycles. The overall
response rate was 10.6% in 85 evaluable patients. The median duration of response was 11 months. The
median survival was 6 months. Toxicity was low, only one patient experiencing toxicity greater than WHO
grade II (grade IV platelet toxicity). Diarrhoea, nausea, vomiting and mucositis also occurred but were mild
and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of
treatment.
Kevwords folinic acid: 5-fluorouracil: colorectal cancer
5-Fluorouracil (5-FU) is the commonest chemotherapeutic
agent used in the treatment of advanced colorectal cancer.
The response rate to single-agent 5-FU in bolus form is only
11% (Advanced Colorectal Meta-Analysis Report, 1992), but
this can be improved when 5-FU is given in combination
with folinic acid (Poon et al., 1991), albeit at the expense of
increased toxicity.
In 1988 de Gramont et al. described a regimen containing
high-dose folinic acid with 5-FU bolus and continuous
infusion in a 2 day, 2 weekly regimen. In patients with
advanced colorectal cancer, there was a high response rate
(54.1%) with low toxicity. Later, Johnson et al. (1991) used
the same regimen against a variety of advanced gastrointes-
tinal malignancies, mainly colorectal. Again it was well
tolerated although the response rate was lower (26%). A
third study comparing this regimen with interferon reported
a response rate of 30% in both arms (Seymour et al., 1994).
However, more recently Jodrell et al. (1994) reported their
experience of the regimen in a retrospective analysis of
patients with advanced colorectal cancer. Toxicity was low
but the response rate was only 11%.
Following the report of de Gramont et al.. our centre
adopted a very similar regimen as first-line chemotherapy for
patients with advanced colorectal cancer. We now present
results from the examination of the case records of patients
treated in Velindre Hospital, Cardiff. UK.
Patients and methods
One hundred patients received the regimen between October
1991 and January 1994. Case records from four patients were
unavailable, leaving 96 for evaluation.
Patient characteristics
All patients had clinical or histological evidence of metastatic
or locally recurrent disease. Eighty-six had proven colorectal
primaries. In the remaining ten, the primary site was un-
known, but from the clinical pattern of disease was thought
to be colorectal. The patient characteristics are shown in Table
I.
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Chemotherapy
The treatment was given as folinic acid 200 mg m-' (max-
imum 300-350 mg) by i.v. infusion over 2 h in 5% dextrose
followed by 5-fluorouracil 400 mg m- in an i.v. bolus then
5-fluorouracil 600 mg m- by i.v. infusion over 22 h in 11
of normal saline. This was repeated over the next 24 h. The
schedule was given every 2 weeks for four cycles provided
there was no clinical evidence of deterioration. Following
this, patients were formally reassessed and only those with
objective tumour response continued treatment, to a max-
imum of eight cycles.
Assessmentfor response
Patients were assessed every 3-8 cycles unless disease pro-
gression occurred. Measurable disease was assessed using
CT scan, chest radiography, ultrasonography or clinical
examination. Standard WHO criteria were applied. In addi-
tion, 15 patients were deemed to have failed to respond to
treatment as their general condition deteriorated neces-
sitating that chemotherapy be abandoned. The median sur-
vival of these 15 was 1 month. Patients unassessable for
response were included in the survival and toxicity data.
Table I Patient characteristics
Characteristic Number ofpatients
Sex
Male 57
Female 39
Age
Median 60
Range 34-70
Site of primary
Colon 59
Rectum 27
Unknown (probably colorectal) 10
Performance status
0-2 84
3-4 12
Previous treatments
Radiotherapy only 12
Chemotherapy only 12
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Statistical methods
Survival data were processed using a BMDP1L life tables
and survivor fractions software package. Comparisons
between responding and non-responding patients were made
with the Mann-Whitnev test.
Results
The case records were studied of 96 patients treated
between October 1991 and January 1994. Eighty-five
patients were evaluable for response (11 not evaluable).
Reasons for inevaluabilitv were: admission to other hos-
pitals and disease not assessed (three patients) or insufficient
information available (eight patients). The median number
of cycles of chemotherapy received was 4 (range 1-8).
Response to chemotherapy
In 85 evaluable patients there were no complete responses
and nine partial responses (10.6°o: 950/0 confidence limits
4.1 -17.1O%). Twenty-nine patients (34.l1°o) had static dis-
ease and 47 patients (55.30/0) had progressive disease. Ten
of the non-responding patients improved symptomatically
during chemotherapy (11.800).
The responding patients were significantly younger than
the non-responders [median age of responding patients 52
years (range 34-66): median age of non-responders 60 years
(range 41-74): P<0.05]. All the patients achieving a partial
response had a WHO performance status of 0 or 1. No
patient receiving fewer than four cycles of chemotherapy
responded to treatment. One of 16 evaluable patients who
had received prior chemotherapy responded.
Surviival following commencement ofchemotherapi
Survival information was available for all 96 patients.
Seventy-six patients have died. The median follow-up time
for survivors was 11 months (range 3-27 months). The
median survival was 6 months. Twenty-seven per cent were
alive at 12 months. The survival curve is represented in
Figure 1. The median survival of the 11 unassessable
patients was similar. 8 months. indicating these were not a
selected group of patients. The median survival of patients
achieving a partial response was 23 months.
Toxicitn'
All 96 patients were included in the toxicitv analvsis. In total.
376 cycles of chemotherapy were administered. The regimen
was verv well tolerated. Only one patient had toxicity greater
than WHO grade II. This patient had received previous
chemotherapy and radiotherapy and suffered grade IV
platelet toxicity after the first cycle. All other side-effects were
WHO grade I or II. Toxicity resulted in delay of only 4 of
376 cycles of chemotherapy. There were no dose reductions.
Nausea or vomniting was seen after 26 cycles (6.9%): and
diarrhoea after 12 cycles (3.2%). Mucositis occurred after 11
cycles (2.900). Platelet toxicity occurred after four cycles
(1.1%). There were no febrile neutropenic episodes.
Discussion
Initial reports of a sirmilar regimen were encouraging in terms
of both response rate and toxicity (de Gramont et al.. 1988:
Johnson et al.. 1991: Seymour et al.. 1994). However a recent
retrospective analysis (Jodrell et al.. 1994) reported a res-
ponse rate of only 1100 although the low toxicitv was
confirmed. Our centre had used the chemotherapy regimen
frequently since 1991 and our study was to investigate how
our response rate and toxicity compared with previous
reports. In common w-ith others. we found the regimen very
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well tolerated. However. our response rate A-as lowx (10.60o).
as was the median survival (6 months).
Our low response rate may have resulted from differences
in patient characteristics and treatment duration compared
with those of the original stud-. The inclusion criteria of the
study by de Gramont et al. included a WHO performance
status of 0-3. a life expectancy of at least 10 weeks. no
history of previous chemotherapy and histological proof of
colorectal cancer.
Performance status is a knowxn predictor of outcome fol-
lowing chemotherapy. In our study all the responding
patients had a WHO performance status of 0 or 1. Also
responding patients were significantly younger than non-
responders: this is not surprising as Young age and good
performance status are likelv to be linked. Our poor response
rate mav reflect the wide inclusion criteria for administering
this regimen in our practice. particularly the inclusion of
patients already deteriorating rapidly because of their disease.
Only I of 16 assessable patients in our studx Awho had
received previous chemotherapy responded. Prior exposure
may have reduced the efficacy of 5-fluorouracil in subsequent
treatments.
Ten patients in this series had carcinoma of unknown
primar-. Some of these may have had other less chemosen-
sitive pnmaries (e.g. lung). However. one patient did res-
pond. indicating that lack of primary per se need not be a
contraindication to treatment. Excluding unknown primary
patients from the analysis does not alter the response rate
significantly (eight partial responses in 76 evaluable patients.
response rate 10.5°00).
In de Gramont et al. s study. patients were treated until
disease progression or 9 months. In Seymour et al. s study.
patients were treated for 12 cycles. with treatment stopped
before this only if there was objective or clinical evidence of
disease progression. In Jodrell et al. s study treatment was
stopped if patients had not achieved a partial response after
2 months and the response rate was lou-er (110°o). In our
study patients received a median of four cycles (2 months).
and we too found a low response rate. In our centre treat-
ment was discontinued if there was no objective response to
spare patients the necessity of 48 h of treatment every 2
weeks. However. the lesser amount of chemotherapy given to
our patients may have resulted in a lower response rate.
Continuing treatment for longer in patients with stable
disease may have allowed more patients to achieve a res-
ponse.
Jodrell et al. (1994) commented that patients receiving
higher doses of 5-FU were more likely to respond. However.
the total dose of 5-FU in their highest dose cohort was the
same as the total dose of 5-FU in our regimen. Therefore.
differences in dose within the range studied could not
account solely for the poor response rate.
In conclusion. our results confirm that this chemotherapy
regimen is well tolerated. and in those patients who respond
a response duration similar to other studies is achieved.
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However. the response rate is low. Our patients were treated
for a relatively short time and might have benefited had the
treatment duration been longer. In addition. some of our
patients were undoubtedly already deteriorating rapidly
because of their disease and did not benefit from chemo-
therapy. Despite the low response rate, some non-responders
did have a symptomatic improvement following chemo-
therapy. We believe the regimen needs further formal evalua-
tion. including quality of life assessment.
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